Atigliflozin

Atigliflozin (AVE2268) is an orally active and selective sodium-glucose co-transporter 2 (SGLT2) inhibitor developed as a potential antidiabetic agent for the treatment of type 2 diabetes. It is a substituted glycopyranoside that acts by inhibiting SGLT2 in the kidneys, thereby reducing glucose reabsorption and increasing urinary glucose excretion, which leads to lower blood glucose levels. Atigliflozin shows high selectivity for SGLT2 over SGLT1 and has minimal effect on intestinal glucose absorption. The drug reached phase II clinical trials but further development was discontinued. The primary developer was Sanofi[1][3][5][7].

Other names

atigliflozin647834-15-9Y0H7UPE4WJY-0H7UPE4WJY 0H7UPE4WJ